Biolife Sciences Stock Buy Hold or Sell Recommendation
| BLFE Stock | USD 0.0001 0.00 0.00% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding BioLife Sciences is 'Strong Sell'. Macroaxis provides BioLife Sciences buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding BLFE positions.
Check out BioLife Sciences Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. Note, we conduct extensive research on individual companies such as BioLife and provide practical buy, sell, or hold advice based on investors' constraints. BioLife Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census.
BioLife |
Execute BioLife Sciences Buy or Sell Advice
The BioLife recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on BioLife Sciences. Macroaxis does not own or have any residual interests in BioLife Sciences or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute BioLife Sciences' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Not Rated
BioLife Sciences Trading Alerts and Improvement Suggestions
| BioLife Sciences generated a negative expected return over the last 90 days | |
| BioLife Sciences has some characteristics of a very speculative penny stock | |
| BioLife Sciences has high likelihood to experience some financial distress in the next 2 years | |
| BioLife Sciences currently holds 398 K in liabilities. BioLife Sciences has a current ratio of 0.07, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist BioLife Sciences until it has trouble settling it off, either with new capital or with free cash flow. So, BioLife Sciences' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like BioLife Sciences sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for BioLife to invest in growth at high rates of return. When we think about BioLife Sciences' use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (456.87 K) with profit before overhead, payroll, taxes, and interest of 0. | |
| BioLife Sciences currently holds about 15.62 K in cash with (106.55 K) of positive cash flow from operations. |
BioLife Sciences Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to BioLife Sciences or Healthcare sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that BioLife Sciences' price will be affected by overall pink sheet market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a BioLife pink sheet's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.00 | |
β | Beta against Dow Jones | 0.00 | |
σ | Overall volatility | 0.00 | |
Ir | Information ratio | 0.00 |
BioLife Sciences Volatility Alert
At this time BioLife Sciences exhibits very low volatility. BioLife Sciences appears to be a penny stock. Although BioLife Sciences may be, in fact, a solid short-term or long term investment, many penny pink sheets are speculative investment instruments that are often subject to artificial stock promotion and campaigns of hype which may lead to misinformation and misrepresentation. Please make sure you fully understand upside potential and downside risks of investing in BioLife Sciences or similar risky assets. We encourage investors to look for signals such as email spams, message board hypes, claims of breakthroughs, volume upswing without any event/news,and sudden news releases. We also encourage traders to check biographies and work history of company President, CEO or other officers before investing in high-volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on BioLife instrument if you perfectly time your entry and exit. However, remember that penny pink sheets that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.BioLife Sciences Fundamentals Vs Peers
Comparing BioLife Sciences' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze BioLife Sciences' direct or indirect competition across all of the common fundamentals between BioLife Sciences and the related equities. This way, we can detect undervalued stocks with similar characteristics as BioLife Sciences or determine the pink sheets which would be an excellent addition to an existing portfolio. Peer analysis of BioLife Sciences' fundamental indicators could also be used in its relative valuation, which is a method of valuing BioLife Sciences by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare BioLife Sciences to competition |
| Fundamentals | BioLife Sciences | Peer Average |
| Current Valuation | 1.01 M | 16.62 B |
| Price To Sales | 0 X | 11.42 X |
| Net Income | (456.87 K) | 570.98 M |
| Cash And Equivalents | 15.62 K | 2.7 B |
| Total Debt | 398 K | 5.32 B |
| Current Ratio | 0.07 X | 2.16 X |
| Book Value Per Share | (0) X | 1.93 K |
| Cash Flow From Operations | (106.55 K) | 971.22 M |
| Earnings Per Share | (0.01) X | 3.12 X |
| Number Of Employees | 3 | 18.84 K |
| Beta | 0.0763 | -0.15 |
| Market Capitalization | 11.45 K | 19.03 B |
BioLife Sciences Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as BioLife . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Rate Of Daily Change | 1.0 | |||
| Day Median Price | 1.0E-4 | |||
| Day Typical Price | 1.0E-4 |
About BioLife Sciences Buy or Sell Advice
When is the right time to buy or sell BioLife Sciences? Buying financial instruments such as BioLife Pink Sheet isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having BioLife Sciences in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Rubber and Plastic Products Thematic Idea Now
Rubber and Plastic Products
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Rubber and Plastic Products theme has 27 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Rubber and Plastic Products Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in BioLife Pink Sheet
BioLife Sciences financial ratios help investors to determine whether BioLife Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in BioLife with respect to the benefits of owning BioLife Sciences security.